Abstract
AbstractBackgroundThis study examines potential, subtle and persistent adverse effects of COVID-19 vaccines on the cardiovascular system. Vaccine-associated myocardial injury was analysed by measuring high-sensitive troponin T (hsTnT); mid-regional pro-adrenomedullin (MR-proADM) levels were evaluated to assess endothelial dysfunction.MethodsThis was a prospective study with a vulnerable population of healthcare workers (HCWs) and elderly patients (> 70 years) who were vaccinated with either one dose of ChAdOx1 nCov-19 adenoviral vector vaccine (AZ) followed by one dose of the BNT162b2 messenger RNA vaccine (BNT), or with two doses of BNT (12thof January - 30thof November 2021). HsTnT and MR-proADM were measured in blood samples at three visits (V1: 1stimmediately before vaccination; V2, 3: 3-4 weeks after 1stand 2ndvaccination). HsTnT of HCWs was compared to a healthy reference population.ResultsN=162 volunteers were included (V1=161; V2, V3=162 each). N=74 (45.7%) received AZ/BNT and n=88 (54.3%) received BNT/BNT (elderly: n=20 (12.3%), HCWs: n=68 (42.0%)). Median hsTnT levels were 4ng/L, 5ng/L and 4ng/L (V1-V3) for AZ/BNT and at 5ng/L, 6ng/L and 6ng/L (V1-V3) for BNT/BNT. Compared to the reference population (n=300), hsTnT was significantly higher at all visits for both vaccination groups (p<0.01), without differences between the AZ/BNT and BNT/BNT cohort. MR-proADM values were 0.43nmol/L, 0.45nmol/L, 0.44nmol/L (V1-V3) in the AZ/BNT cohort and 0.49nmol/L, 0.44nmol/L, 0.47nmol/L for BNT/BNT, respectively. Change of median hsTnT and MR-proADM between visits did not show significant increases. One HCW case had a permanent and three a transient hsTnT increase ≥14ng/L.ConclusionWith one individual exception, no overall subtle, persistent cardiovascular involvement was observed after the 2ndCOVID-19 vaccination.Structured graphical abstractSummary of the vaccination scheme and visiting points in the study population (of HCWs and seniors > 70 years) between the 12thof January and the 30thof November 2021. The results showed no overall subtle, chronic myocardial or vascular involvement in our COVID-19 vaccinated cohorts.Abbreviations:AZ ChAdOx1 nCov-19 adenoviral vector vaccine from Astra Zeneca, BNT BNT162b2 messenger ribonucleic acid vaccine from BioNTech, EDTA Ethylenediaminetetraacetic acid, HCWs health care workers, hsTnT high-sensitive troponin T, mid-regional pro-adrenomedullin, V1-V3visiting times 1-3, w week(s).
Publisher
Cold Spring Harbor Laboratory
Reference35 articles.
1. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study
2. The effectiveness of COVID-19 vaccines in reducing the incidence, hospitalization, and mortality from COVID-19: A systematic review and meta-analysis;Front Public Health,2022
3. University of Oxford. Coronavirus (COVID-19) vaccinations. 2023. Available from: https://ourworldindata.org/covid-vaccinations. Last accessed: 04 August 2023.
4. Centers for Disease Control and Prevention. Selected Adverse Events Reported after COVID-19 Vaccination. 2023. Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/adverse-events.html. Last accessed: 04 August 2023.
5. European Medicines Agency. Safety of COVID-19 vaccines. 2023. Available from: https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/covid-19-medicines/safety-covid-19-vaccines#:~:text=Reports%20of%20suspected%20side%20effects,-Information%20on%20reports&text=Almost%20768%20million%20vaccine%20doses,every%20100%20administered%20vaccine%20doses. Last accessed: 04 August 2023.